Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,053 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Toxic Epidermal Necrolysis
Interventions: Isotretinoin, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 69 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria
Interventions: THB335 Lower Dose, THB335 Higher Dose, Placebo; Drug
Lead sponsor: Calixis Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 15
States / cities: Pasadena, California • Ventura, California • Walnut Creek, California + 12 more

Conditions: Atopic Dermatitis, Vitamin D Deficiency
Interventions: Vitamin D; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 1 Year to 18 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hereditary Angioedema, HAE
Interventions: BCX4161, Placebo; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 25
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Granada Hills, California + 21 more

Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema
Interventions: Crisaborole 2% Top Oint, Skin Microbiome Swabs; Drug · Genetic
Lead sponsor: University of California, Irvine; Other
Eligibility: 2 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Irvine, California

Conditions: Hypersensitivity
Interventions: Butenafine HCl 1% (BAY1896425); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Fairfield, New Jersey

Conditions: Atopic Dermatitis
Interventions: Abrocitinib 200 mg, Dupilumab 300 mg; Drug · Combination Product
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 727 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 49
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 39 more

Conditions: Allergy, Hypersensitivity, Immediate, Ig-E Mediated Food
Interventions: AllerTest-10 Multi-Head Skin Test Device, Skintestor OMNI Multi-Head Skin Test Device, Multi-Test II Multi-Head Skin Test Device, AllerTest-8 Multi-Head Skin Test Device; Device
Lead sponsor: QHSLab, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Atopic Dermatitis
Interventions: 0417, Vehicle of 0417 test product, Tacrolimus Ointment 0.03%; Drug
Lead sponsor: Fougera Pharmaceuticals Inc.; Industry
Eligibility: 8 Years and older
Enrollment: 899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Melville, New York

Conditions: Dermatitis, Atopic
Interventions: Bathing Additive; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 6 Months to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer
Interventions: chemotherapy, endocrine therapy, DNA methylation analysis, protein analysis, laboratory biomarker analysis, questionnaire administration, adjuvant therapy, conventional surgery, radiation therapy; Drug · Genetic · Other + 2 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Cancer, Metastatic Cancer, Breast Cancer
Interventions: ART4215, Talazoparib, Niraparib; Drug
Lead sponsor: Artios Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 7
States / cities: New Haven, Connecticut • Orlando, Florida • New York, New York + 4 more

Conditions: Eczema, Dermatitis, Dermatitis, Atopic, Genetic Disease, Inborn, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases, Skin Diseases, Skin Diseases, Eczematous, Skin Diseases, Genetic
Interventions: Care provided by general pediatrician, Care provided by pediatric dermatologist; Other
Lead sponsor: Yale University; Other
Eligibility: Up to 7 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Stage I Breast Cancer
Interventions: Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane); Other · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 50 Years to 70 Years
Enrollment: 1,670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2041
U.S. locations: 812
States / cities: Birmingham, Alabama • Mobile, Alabama • Kingman, Arizona + 553 more

Conditions: Atopic Dermatitis
Interventions: pimecrolimus, topical medical device; Drug · Device
Lead sponsor: Emer, Jason, M.D.; Individual
Eligibility: 2 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Bilastine, Bilastine & Ketoconazole, Moxifloxacin, Placebo; Drug
Lead sponsor: Faes Farma, S.A.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Chronic Urticaria
Interventions: AK002; Drug
Lead sponsor: Allakos Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Edgewater, Florida • Cincinnati, Ohio

Conditions: Asthma, Rhinitis, Eczema, Respiratory Sounds, Hypersensitivity
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 6 Years to 11 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Atopic Dermatitis, Eczema
Interventions: Moisturizer with each subject's own antimicrobial bacteria; Biological
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
Interventions: Sparsentan; Drug
Lead sponsor: Travere Therapeutics, Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 23
States / cities: Los Angeles, California • Wilmington, Delaware • Miami, Florida + 17 more

Conditions: Atopic Dermatitis
Interventions: Sponsor Test Products; Other
Lead sponsor: Burt's Bees Inc.; Industry
Eligibility: 6 Months to 7 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: Hereditary Angioedema (HAE)
Interventions: DX-2930; Drug
Lead sponsor: Shire; Industry
Eligibility: 12 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 31
States / cities: Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 28 more

Conditions: Type I Hypersensitivity
Interventions: Grass MATA MPL; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Atopic Dermatitis
Interventions: Text message to cell phone; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 10 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Chicago, Illinois

Search by objective public record fields.

Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study

A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)

Vitamin D Deficiency and Atopic Dermatitis

12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks

Characterizing Skin Microbiome Change in Atopic Dermatitis

Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Head-to-Head Comparison Study Between Different FDA Registered Allergy Skin Test Applicators

Study of 0417 Ointment in the Treatment of Atopic Dermatitis

Bathing Additives in Pediatric Atopic Dermatitis

Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.

A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine

A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria

Oral Bacteria and Allergic Disease in Children

Evaluation of the Kinetic Properties of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer

Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing

Text Messaging and Atopic Dermatitis